CORONAVIRUS/Taiwan synthesizes anti-viral drug favilavir for COVID-19 patients

03/02/2020 05:21 PM
To activate the text-to-speech service, please first agree to the privacy policy below.

Taipei, March 2 (CNA) Taiwan's non-profit Development Center for Biotechnology (DCB) announced Monday that it has synthesized favilavir, an experimental medication being used in other countries as an investigational therapy to combat the COVID-19 coronavirus.

(Full text of the story is now in CNA English news archive. To view the full story, you will need to be a subscribed member of the CNA archive. To subscribe, please read here.)

View All
We value your privacy.
Focus Taiwan (CNA) uses tracking technologies to provide better reading experiences, but it also respects readers' privacy. Click here to find out more about Focus Taiwan's privacy policy. When you close this window, it means you agree with this policy.